Baxter to Acquire Fusion Medical for $157 Million

In a move that will expand its line of biotherapeutic products for surgery, Baxter International, Inc. (Deerfield, IL, USA) has agreed to acquire Fusion Medical Technologies (Fremont, CA, USA) for about US$157 million in stock.

Fusion's primary product, FloSeal, is a combination of engineered collagen-derived particles and topical thrombin designed to control bleeding during surgery. The product is being marketed as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical. Fusion also has other products in development based on a bioresorbable, proprietary collagen-based gel.

Baxter's BioScience business supplies innovative products for biosurgery and tissue regeneration. Its principal product is Tisseel VH fibrin sealant, which is offered with a complete line of application devices. The company says Tisseel has been used in more than eight million surgeries worldwide.

"Fusion's expertise in collagen and gelatin-based products complements Baxter's strength in fibrin-based technologies,” noted Thomas Glanzmann, president of Baxter BioScience. "With the combination, we will be able to offer surgeons an array of solutions to seal tissue, enhance wound healing, and manage hemostasis, now including active bleeding.”





Related Links:
Baxter
Fusion